PMID- 28282271
OWN - NLM
STAT- MEDLINE
DCOM- 20180112
LR  - 20211204
IS  - 1557-7465 (Electronic)
IS  - 1079-9907 (Linking)
VI  - 37
IP  - 3
DP  - 2017 Mar
TI  - Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in 
      HCV and HIV-Coinfected Patients.
PG  - 103-111
LID - 10.1089/jir.2016.0082 [doi]
AB  - To evaluate the efficacy and safety of pegylated interferon-lambda-1a 
      (Lambda)/ribavirin (RBV)/daclatasvir (DCV) for treatment of patients coinfected 
      with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV). 
      Treatment-naive patients were assigned to cohort A [HCV genotype (GT)-2 or -3] or 
      cohort B [HCV GT-1(a or b) or -4]. All patients received Lambda/RBV/DCV for the 
      first 12 weeks; cohort A received Lambda/RBV for an additional 12 weeks, followed 
      by 24 weeks of follow-up, and cohort B received response-guided therapy. The 
      primary endpoint was the proportion of patients who achieved a sustained 
      virologic response at post-treatment week 12 (SVR12). In cohort A (n = 104), 
      84.6% achieved SVR12 (95.0% in GT-2; 83.1% in GT-3). In cohort B (n = 196), 76.0% 
      achieved SVR12 (71.7% in GT-1a; 86.0% in GT-1b; 70.7% in GT-4). Rates of 
      discontinuation due to adverse events (AEs) (3.8% and 6.1%) and serious AEs (5.8% 
      and 6.1%) were low in cohorts A and B, respectively. In addition, treatment with 
      Lambda/RBV/DCV had little impact on CD4 counts. SVR12 rates with Lambda/RBV/DCV 
      in an HCV/HIV-coinfected population ranged from 71.7% to 95.0%. Treatment was 
      generally well tolerated, with a low proportion of patients discontinuing due to 
      AEs. Clinical trial registration NCT01866930.
FAU - Nelson, Mark
AU  - Nelson M
AD  - 1 Chelsea and Westminster Hospital , London, United Kingdom .
FAU - Rubio, Rafael
AU  - Rubio R
AD  - 2 Hospital Universitario 12 Octubre , Centro de Actividades Ambulatorias, Madrid, 
      Spain .
FAU - Lazzarin, Adriano
AU  - Lazzarin A
AD  - 3 Scientific Institute Ospedale , San Raffaele, Milan, Italy .
FAU - Romanova, Svetlana
AU  - Romanova S
AD  - 4 State Research Center-Institute of Biophysics , Russian Ministry of Health, 
      Moscow, Russia .
FAU - Luetkemeyer, Annie
AU  - Luetkemeyer A
AD  - 5 Zuckerberg San Francisco General, University of California , San Francisco, San 
      Francisco, California.
FAU - Conway, Brian
AU  - Conway B
AD  - 6 Vancouver Infectious Diseases Centre , Vancouver, Canada .
FAU - Molina, Jean-Michel
AU  - Molina JM
AD  - 7 Department of Infectious Diseases, Hopital Saint-Louis, Assistance Publique 
      Hopitaux de Paris, University of Paris Diderot , Paris, France .
FAU - Xu, Dong
AU  - Xu D
AD  - 8 Bristol-Myers Squibb , Wallingford, Connecticut.
FAU - Srinivasan, Subasree
AU  - Srinivasan S
AD  - 8 Bristol-Myers Squibb , Wallingford, Connecticut.
FAU - Portsmouth, Simon
AU  - Portsmouth S
AD  - 9 Shionogi Inc. , Florham Park, New Jersey.
LA  - eng
SI  - ClinicalTrials.gov/NCT01866930
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170217
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Carbamates)
RN  - 0 (Imidazoles)
RN  - 0 (Pyrrolidines)
RN  - 0 (interferon-lambda, human)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
RN  - HG18B9YRS7 (Valine)
RN  - LI2427F9CI (daclatasvir)
SB  - IM
MH  - Adult
MH  - Aged
MH  - CD4 Lymphocyte Count
MH  - Carbamates
MH  - *Coinfection
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - HIV Infections/immunology/*virology
MH  - Hepacivirus/*genetics
MH  - Hepatitis C/*drug therapy/*virology
MH  - Humans
MH  - Imidazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Interferons/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pyrrolidines
MH  - Ribavirin/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Valine/analogs & derivatives
MH  - Viral Load
OTO - NOTNLM
OT  - IFN receptors
OT  - IFNs and cytokines
OT  - antiviral actions
OT  - infectious disease
EDAT- 2017/03/11 06:00
MHDA- 2018/01/13 06:00
CRDT- 2017/03/11 06:00
PHST- 2017/03/11 06:00 [entrez]
PHST- 2017/03/11 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 10.1089/jir.2016.0082 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2017 Mar;37(3):103-111. doi: 10.1089/jir.2016.0082. 
      Epub 2017 Feb 17.